5 Ways to improve ICER’s value assessment framework

The Institute for Clinical and Economic Review’s (ICER) recently made a call for suggestions and feedback on how to improve its value assessment framework and methods. We are a strong supporter of...
Read More
Assessing value top of mind at ISPOR 2019

As we move toward a value-driven health care system, the focus should be on outcomes that matter most to patients, such as how medicines make patients feel, whether they can return to work or how...
Read More
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid

A new analysis from Xcenda found that if Medicaid were to use one-size-fits-all value assessments like the Institute for Clinical and Economic Review’s (ICER) framework as the basis for accessing a...
Read More
Value assessments should include all the outcomes that matter to patients and families

Value assessments are an important tool in moving toward better, more affordable health care. When it comes to assessing the value of medicines, we need approaches that reflect what matters to...
Read More
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care

Tomorrow, October 3, PhRMA will convene health care leaders for a discussion on how we can move our health care system toward one focused on value rather than volume, ensuring patients can access the...
Read More
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers

A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be...
Read More
Guest post: Developing new payment models to ensure patients have access to high-investment therapies

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Number of value-based contracts continues to rise

The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter – from...
Read More
ICER’s budget impact threshold: Sounding a false alarm on affordability and access

If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?
Read More
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....
Read More